2084 J ournal of Medicinal Chemistry, 1999, Vol. 42, No. 12
Holy´ et al.
adefovir dipivoxil: in vitro dissolution and in vivo bioavailability
in dogs. J . Pharm. Sci. 1997, 86, 1334-1338. (g) De Clercq, E.
New perspectives for the treatment of HIV infections. Collect.
Czech. Chem. Commun. 1998, 63, 449-479.
latory properties of 9-[2-(phosphonomethoxy)ethyl]adenine
(PMEA). Folia Biol. Prague 1994, 40, 185-192. (d) Villani, N.;
Calio, R.; Balestra, E.; Balzarini, J .; De Clercq, E.; Fabrizi, E.;
Perno, C. F.; Del Gobbo, V. 9-(2-phosphonylmethoxyethyl)-
adenine increases the survival of influenza virus-infected mice
by an enhancement of the immune system. Antiviral Res. 1994,
25, 81-89. (e) Calio, R.; Villani, N.; Balestra, E.; Sesa, F.; Holy´,
A.; Balzarini, J .; De Clercq, E.; Perno, C. F.; Del Gobbo, V.
Enhancement of natural killer activity and interferon induction
by different acyclic nucleoside phosphonates. Antiviral Res. 1994,
23, 77-89. (f) Z´ıdek, Z.; Holy´, A.; Frankova´, D.; Otova´, B.
Suppression of rat adjuvant arthritis by some acyclic nucleotide
analogues. Eur. J . Pharmacol. 1995, 286, 307-310. (g) Z´ıdek,
Z.; Frankova´, D.; Holy´, A.; Boubel´ık, M.; Dra´ber, P. Inhibition
of murine macrophage nitric oxide synthase expression by a
pivoxil prodrug of antiviral acyclic nucleotide analogue 9-(2-
phosphonomethoxyethyl)adenine. Biochem. Pharmacol. 1997,
54, 855-861. (h) Balzarini, J .; Verstuyf, A.; Hatse, S.; Goebels,
J .; Sobis, H.; Vandeputte, M.; De Clercq, E. The human immu-
nodeficiency virus (HIV) inhibitor 9-(2-phosphonylmethoxy-
ethyl)adenine (PMEA) is a strong inducer of differentiation of
several tumor cell lines. Int. J . Cancer 1995, 61, 130-137. (i)
Hatse, S.; De Clercq, E.; Balzarini, J . The role of antimetabolites
of purine and pyrimidine metabolism in tumor cell differentia-
tion. Biochem. Pharmacol. 1998, in press.
(11) Cundy, K. C.; Barditch-Crovo, P. A.; Walker, R. E.; Collier, A.
C.; Ebeling, D.; Toole, J .; J affe, H. S. Clinical pharmacokinetics
of adefovir in human immunodeficiency virus type 1-infected
patients. Antimicrob. Agents Chemother. 1995, 39, 2401-2405.
(12) (a) Heijtink, R. A.; Dewilde, G. A.; Kruining, J .; Berk, L.;
Balzarini, J .; De Clercq, E.; Holy´, A.; Schalm, S. W. Inhibitory
effect of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) on hu-
man and duck hepatitis-B virus infection. Antiviral Res. 1993,
21, 141-153. (b) Yokota, T.; Konno, K.; Shigeta, S.; Holy´, A.;
Balzarini, J .; De Clercq, E. Inhibitory effects of acyclic nucleoside
phosphonate analogues on hepatitis B virus DNA synthesis in
Hb611 Cells. Antivir. Chem. Chemother. 1994, 5, 57-63. (c)
Balzarini, J .; Kruining, J .; Heijtink, R.; De Clercq, E. Compara-
tive anti-retrovirus and anti-hepadnavirus activity of three
different classes of nucleoside phosphonate derivatives. Antivir.
Chem. Chemother. 1994, 5, 360-365.
(13) (a) Holy´, A.; Votruba, I.; Merta, A.; Cˇ erny´, J .; Vesely´, J .; Vlach,
J .; Sˇediva´, K.; Rosenberg, I.; Otmar, M.; Hrˇebabecky´, H.;
Tra´vn´ıcˇek, M.; Vonka, V.; Snoeck, R.; De Clercq, E. Acyclic
nucleotide analogues: synthesis, antiviral activity and inhibition
effects on some cellular and virus-encoded enzymes in vitro.
Antiviral Res. 1990, 13, 295-312. (b) Merta, A.; Votruba, I.;
Rosenberg, I.; Otmar, M.; Hrˇebabecky´, H.; Bernaerts, R.; Holy´,
A. Inhibition of herpes simplex virus DNA polymerase by
diphosphates of acyclic phosphonylmethoxyalkyl nucleotide
analogues. Antiviral Res. 1990, 13, 209-218. (c) Foster, S. A.;
Cˇ erny´, J .; Cheng, Y. C. Herpes simplex virus-specified DNA
polymerase is the target for the antiviral action of 9-(2-phos-
phonylmethoxyethyl)adenine. J . Biol. Chem. 1991, 266, 238-
244. (d) Robbins, B. L.; Greenhaw, J .; Connelly, M. C.; Fridland,
A. Metabolic pathways for activation of the antiviral agent 9-(2-
phosphonylmethoxyethyl)adenine in human lymphoid cells. An-
timicrob. Agents Chemother. 1995, 39, 2304-2308.
(20) (a) Baba, M.; Konno, K.; Shigeta, S.; De Clercq, E. In vitro
activity of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine
against newly isolated clinical varicella-zoster virus strains. Eur.
J . Clin. Microbiol. Infect. Dis. 1987, 6, 158-160. (b) Maudgal,
P. C.; De Clercq, E.; Huyghe, P. Efficacy of (S)-HPMPA against
thymidine kinase deficient herpes simplex virus keratitis. Invest.
Ophthalmol. Vis. Sci. 1987, 28, 243-248. (c) Mul, Y. M.; van
Miltenburg, R. T.; De Clercq, E.; Van der Vliet, P. C. Mechanism
of inhibition of adenovirus DNA replication by the acyclic
nucleoside triphosphate analogue (S)-HPMPApp; influence of the
adenovirus DNA binding protein. Nucl. Acids Res. 1989, 17,
8917-8929.
(14) Merta, A.; Vesely´, J .; Votruba, I.; Rosenberg, I.; Holy´, A.
Phosphorylation of acyclic nucleotide analogues HPMPA and
PMEA in L-1210 mouse leukemic cell extracts. Neoplasma 1990,
37, 111-120.
(15) Balzarini, J .; De Clercq, E. 5-Phosphoribosyl 1-pyrophosphate
synthetase converts the acyclic nucleoside phosphonates 9-(3-
hydroxy-2-phosphonylmethoxypropyl)adenine and 9-(2-phos-
phonylmethoxyethyl)adenine directly to their antivirally ac-
tive diphosphate derivatives. J . Biol. Chem. 1991, 266, 8686-
8689.
(16) Kramata, P.; Votruba, I.; Otova´, B.; Holy´, A. Different inhibitory
potencies of acyclic phosphonomethoxyalkyl nucleotide analogues
toward DNA polymerases R, δ and ꢀ. Mol. Pharmacol. 1996, 49,
1005-1011.
(17) (a) Votruba, I.; Tra´vn´ıcˇek, M.; Rosenberg, I.; Otmar, M.; Merta,
A.; Hrˇebabecky´, H.; Holy´, A. Inhibition of AMV(MAV) reverse
transcriptase by diphosphates of acyclic nucleotide analogues.
Antiviral Res. 1990, 13, 287-294. (b) Balzarini, J .; Hao, Z.;
Herdewijn, P.; J ohns, D. G.; De Clercq, E. Intracellular metabo-
lism and mechanism of anti-retrovirus action of 9-(2-phospho-
nylmethoxyethyl)adenine, a potent anti-human immunodefi-
ciency virus compound. Proc. Natl. Acad. Sci. U.S.A. 1991, 88,
1499-1503.
(18) (a) Vesely´, J .; Merta, A.; Votruba, I.; Rosenberg, I.; Holy´, A. The
cytostatic effects and mechanism of action of antiviral acyclic
adenine nucleotide analogues in L1210 mouse leukemia cells.
Neoplasma 1990, 37, 105-110. (b) Otova´, B.; Sladka´, M.;
Votruba, I.; Holy´, A.; Krˇen, V. Cytostatic effect of 9-[2-(phospho-
nomethoxy)ethyl]adenine (PMEA). 1. Lymphatic leukemia KHP-
Lw-I in Lewis rats. Folia Biol. Prague 1993, 39, 136-141. (c)
Otova´, B.; Sladka´, M.; Blazˇek, K.; Schramlova´, J .; Votruba, I.;
Holy´, A. Cytostatic Effect of 9-[2-(phosphonomethoxy)ethyl]-
adenine (PMEA). 2. Lymphoblastic leukemia in Sprague-Dawley
rats. Folia Biol. Prague 1993, 39, 142. (d) Otova´, B.; Krˇenova´,
D.; Z´ıdek, Z.; Holy´, A.; Votruba, I.; Krˇen, V. Cytostatic Effect of
9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). 3. Rat and Mouse
Carcinomas and Sarcomas. Folia Biol. Prague 1993, 39, 311-
314. (e) Hatse, S.; Naesens, L.; Degreve, B.; Segers, C.;
Vandeputte, M.; Waer, M.; De Clercq, E.; Balzarini, J . Potent
antitumor activity of the acyclic nucleoside phosphonate 9-(2-
phosphonylmethoxyethyl)adenine in choriocarcinoma-bearing
rats. Int. J . Cancer 1998, 76, 595-600.
(19) (a) Del Gobbo, V.; Foli, A.; Balzarini, J .; De Clercq, E.; Balestra,
E.; Villani, N.; Marini, S.; Perno, C. F.; Calio, R. Immunomodu-
latory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA),
a potent anti-HIV nucleotide analogue, on in vivo murine models.
Antiviral Res. 1991, 16, 65-75. (b) Krˇen, V.; Otova´, B.; Elleder,
D.; Elleder, M.; Panczak, A.; Holy´, A. Prevention of acute graft-
versus-host disease in rats using 9-[2-(phosphonomethoxy)ethyl]-
adenine (PMEA). Folia Biol. Prague 1993, 39, 78-86. (c) Otova´,
B.; Z´ıdek, Z.; Holy´, A.; Votruba, I.; Frankova´, D. Immunomodu-
(21) (a) Terry, B. J .; Mazina, K. E.; Tuomari, A. V.; Haffey, M. L.;
Hagen, M.; Feldman, A.; Slusarchyk, W. A.; Young, M. G.;
Zahler, R.; Field, A. K. Broad-spectrum antiviral activity of the
acyclic guanosine phosphonate (R,S)-HPMPG. Antiviral Res.
1988, 10, 235-251. (b) Yu, KL.; Bronson, J . J .; Yang, H.; Patick,
A.; Alam, M.; Brankovan, V.; Datema, R.; Hitchcock, M. J .;
Martin, J . C. Synthesis and antiviral activity of methyl deriva-
tives of 9-[2-(phosphonomethoxy)ethyl]guanine. J . Med. Chem.
1992, 35, 2958-2969. (c) Smee, D. F.; Barnett, B. B.; Sidwell,
R. W.; Reist, E. J .; Holy´, A. Antiviral activities of nucleosides
and nucleotides against wild-type and drug-resistant strains of
murine cytomegalovirus. Antiviral Res. 1995, 26, 1-9.
(22) (a) Neyts, J .; Snoeck, R.; Balzarini, J .; De Clercq, E. Particular
characteristics of the anti-human cytomegalovirus activity of (S)-
1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in
vitro. Antiviral Res. 1991, 16, 41-52. (b) De Clercq, E. Thera-
peutic potential of HPMPC as an antiviral drug. Rev. Med. Virol.
1993, 3, 85-96. (c) Holy´, A. Syntheses of enantiomeric N-(3-
hydroxy-2-phosphonomethoxypropyl) derivatives of purine and
pyrimidine bases. Collect. Czech. Chem. Commun. 1993, 58,
649-674. (d) Flores-Aguilar, M.; Huang, J .-S.; Wiley: C. A.; De
Clercq, E.; Vuong, C.; Bergeron-Lynn, G. L.; Chandler, B.; Mun-
guia, D.; Freeman, W. R. Long-acting therapy of viral retinitis
with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J .
Infect. Dis. 1994, 169, 642-647. (e) Kirsch, L. S.; Arevalo, J . F.;
Delapaz, E. C.; Munguia, D.; De Clercq, E.; Freeman, W. R.
Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus
retinitis in patients with acquired immune deficiency syndrome.
Ophthalmology 1995, 102, 533-542. (f) Blick, G.; Garton, T.;
Hopkins, U.; Lagravinese, L. Successful use of cidofovir in
treating AIDS-related cytomegalovirus retinitis, encephalitis,
and esophagitis. J . Acquired Immune Defic. Syndr. Hum. Retro-
virol. 1997, 15, 84-85. (g) Naesens, L.; De Clercq, E. Therapeutic
potential of HPMPC (cidofovir), PMEA (adefovir) and related
acyclic nucleoside phosphonate analogues as broad-spectrum
antiviral agents. Nucleos. Nucleot. 1997, 16, 983-992. (h)
Lalezari, J . P.; Holland, G. N.; Kramer, F.; McKinley, G. F.;
Kemper, C. A.; Ives, D. V.; Nelson, R.; Hardy, W. D.; Kupper-
mann, B. D.; Northfelt, D. W.; Youle, M.; J ohnson, M.; Lewis,
R. A.; Weinberg, D. V.; Simon, G. L.; Wolitz, R. A.; Ruby, A. E.;
Stagg, R. J .; J affe, H. S. Randomized, controlled study of the
safety and efficacy of intravenous cidofovir for the treatment of
relapsing cytomegalovirus retinitis in patients with AIDS. J .
Acquired Immune Defic. Syndr. Hum. Retrovirol. 1998, 17, 339-
344.
(23) (a) Hitchcock, M. J . M.; J affe, H. S.; Martin, J . C.; Stagg, R. J .
Cidofovir, a new agent with potent anti-herpesvirus activity -
Review: Antiviral portrait series. Antivir. Chem. Chemother.
1996, 7, 115-127. (b) Lea, A. P.; Bryson, H. M. Cidofovir. Drugs
1996, 52, 225-230. (c) Rahhal, F. M.; Arevalo, J . F.; Munguia,
D.; Taskintuna, I.; Delapaz, E. C.; Azen, S. P.; Freeman, W. R.